Potassium2026-07

Emerging Strategies for Cardio-Renal Protection Beyond RAAS Blockade: .

Alrashidi Fahad S — Saudi medical journal

Summary

This paper reviews new medical approaches to protect the heart and kidneys, especially for people with chronic kidney disease and high blood pressure that's hard to control. It highlights several emerging drug classes that offer benefits beyond standard treatments. Importantly, it emphasizes that carefully managing potassium levels is crucial for some of these new therapies to be effective and safe.

AI-generated summary — read the original

Key points

New medical strategies are emerging to better protect the heart and kidneys, especially for resistant high blood pressure.
Certain new medications, like SGLT2 inhibitors and non-steroidal MRAs, offer additional benefits for cardio-renal health.
Careful management of potassium levels is essential when using some of these advanced kidney and heart protective drugs.
Modern potassium binders can help patients continue effective treatments for high blood pressure and kidney disease.

What the study looked at

This review paper explored new and emerging medical strategies for protecting the heart and kidneys in individuals with non-diabetic chronic kidney disease complicated by resistant hypertension, looking beyond traditional blood pressure medications. Researchers synthesized and evaluated contemporary evidence from clinical trials and existing research on various drug classes and treatment approaches. It did not involve new participants but rather reviewed data from previously conducted studies. What it found: The review identified several promising new treatments, including SGLT2 inhibitors, which offer kidney and heart failure risk reduction. It also highlighted non-steroidal mineralocorticoid receptor antagonists (MRAs) as beneficial, provided potassium levels are proactively managed. GLP-1 receptor agonists showed cardiometabolic advantages, and modern potassium binders were noted for their ability to help maintain optimal treatment intensity. Device-based strategies for blood pressure were also mentioned for specific cases.

Dietary takeaway

For individuals with chronic kidney disease and resistant hypertension, this review suggests new medications can offer significant heart and kidney protection. While these advanced treatments are promising, it's crucial to work closely with your doctor to monitor and manage potassium levels, as some medications require careful attention. Specific dietary adjustments related to potassium should always be discussed with a healthcare professional, as one study is not definitive and individual needs vary.

Abstract

Non-diabetic chronic kidney disease (ND-CKD) complicated by resistant hypertension remains a high-risk phenotype even when renin-angiotensin system blockade is optimized. This review synthesizes contemporary evidence for cardio-renal protection beyond traditional renin-angiotensin-aldosterone system inhibition (RAASi), with emphasis on mechanisms, clinical trial data, and pragmatic sequencing. Sodium-glucose cotransporter 2 inhibitors provide hemodynamic and tubular benefits that translate into renal and heart failure risk reduction in many patients with ND-CKD. Non-steroidal mineralocorticoid receptor antagonism (MRA) like finerenone targets inflammatory and fibrotic signaling and may add incremental benefit when potassium is proactively managed. The GLP-1 receptor agonists offer cardiometabolic advantages with emerging kidney signals, particularly in patients with obesity and high cardiovascular risk. Modern potassium binders can preserve RAASi/MRA intensity, and device-based blood pressure strategies (including renal denervation) may be considered in carefully selected resistant hypertension. We propose a stepwise implementation framework to maximize efficacy while minimizing adverse events through structured monitoring and multidisciplinary care.

View on PubMed →DOI: 10.15537/1658-3175.8819